Literature DB >> 32652632

Daratumumab for disabling cold agglutinin disease refractory to B-cell directed therapy.

Oliver Tomkins1, Sigbjørn Berentsen2, Suzanne Arulogun1, Mallika Sekhar1, Shirley D'Sa1.   

Abstract

Entities:  

Year:  2020        PMID： 32652632     DOI： 10.1002/ajh.25932

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  4 in total

1.  Case Report: Resetting the Humoral Immune Response by Targeting Plasma Cells With Daratumumab in Anti-Phospholipid Syndrome.

Authors:  Daniel E Pleguezuelo; Raquel Díaz-Simón; Oscar Cabrera-Marante; Antonio Lalueza; Estela Paz-Artal; Carlos Lumbreras; Antonio Serrano Hernández
Journal:  Front Immunol       Date:  2021-04-12       Impact factor: 7.561

2.  The Immunomodulatory Effect and Clinical Efficacy of Daratumumab in a Patient With Cold Agglutinin Disease.

Authors:  Anna Zaninoni; Juri A Giannotta; Anna Gallì; Rosangela Artuso; Paola Bianchi; Luca Malcovati; Wilma Barcellini; Bruno Fattizzo
Journal:  Front Immunol       Date:  2021-03-01       Impact factor: 7.561

Review 3.  IgM monoclonal gammopathies of clinical significance: diagnosis and management.

Authors:  Jahanzaib Khwaja; Shirley D'Sa; Monique C Minnema; Marie José Kersten; Ashutosh Wechalekar; Josephine M Vos
Journal:  Haematologica       Date:  2022-09-01       Impact factor: 11.047

Review 4.  HLA Desensitization in Solid Organ Transplantation: Anti-CD38 to Across the Immunological Barriers.

Authors:  Nizar Joher; Marie Matignon; Philippe Grimbert
Journal:  Front Immunol       Date:  2021-05-20       Impact factor: 7.561
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.